The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://allenjtkd022032.ja-blog.com/39284096/glp-3-retatrutide-a-comparative-analysis